NCT01179529已完成2 期
Single- Arm Trial to Identify Potential Markers Underlying Variability in Response to Omalizumab (Xolair®) Treatment in Atopic Dermatitis
Technical University of Munich1 个研究点 分布在 1 个国家开始时间: 2010年8月11日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 试验地点
- 1
- 主要终点
- To evaluate efficacy of Omalizumab treatment in a sample of adult patients with moderate to severe AD
研究概览
简要总结
This study aims at evaluating the therapeutic potential of omalizumab in atopic dermatitis, and to work out biomarkers predictive of treatment response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18-70 years of age, body weight ≥ 20 kg and ≤ 150 kg
- •Dermatological diagnosis of AD, SCORAD >=20
- •A positive RAST (≥CAP1) result for at least one aeroallergen specific IgE and total IgE >=100kU/l at screening (or within the previous 12 months)
- •Eligible to receive systemic therapy for AD in accordance to local guidelines
- •Signed informed consent from patient
排除标准
- •Evidence of skin disease other than AD (e.g. psoriasis) at the inclusion time
- •Treatment with systemic AD medications or any investigational drug within a 30-day washout period
- •Concomitant treatment with substances interfering with the immune system
- •Permanent severe diseases, especially those affecting the immune system, except asthma
- •Pregnancy or breast feeding
- •History of food or drug related severe anaphylactoid or anaphylactic reaction(s)
- •History or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia
- •History or presence of myocardial infarction or cardiac arrhythmia which requires drug therapy
- •Elevated serum IgE levels for reasons other than allergy and/or urticaria (e.g.: parasite infections, hyperimmunoglobulin E syndrome, Wiskott - Aldrich syndrome or clinical allergic bronchopulmonary aspergillosis)
- •Evidence of severe renal dysfunction or significant hepatic disease
- •Evidence for active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy
- •History of malignancy of any organ system, treated or untreated, whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin
- •Clinically significant laboratory abnormalities (not associated with AD) at Visit 1
- •Known hypersensitivity to any ingredients, including excipients (sucrose, histidine, polysorbate 20) of the study medication or drugs related to Omalizumab (e.g.: monoclonal antibodies, polyclonal gammaglobulin)
- •Patients who are considered potentially unreliable or where it is envisaged the patient may not consistently attend scheduled study visits
- •Patients with serious psychiatric and/or psychological disturbances
- •Patients with a history of drug or alcohol abuse
- •Patients who are unable to complete a patient diary or complete questionnaires on paper
- •Patients with any other condition or prior/current treatment, which in the opinion of the investigator renders the patient ineligible for the study schedule
研究组 & 干预措施
Omalizumab
Experimental
干预措施: Omalizumab (Xolair®) (Drug)
结局指标
主要结局
To evaluate efficacy of Omalizumab treatment in a sample of adult patients with moderate to severe AD
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema TrialModerate-to-Severe Atopic DermatitisAtopic EczemaNCT05590585Regeneron Pharmaceuticals124
已完成
2 期
Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic DermatitisAtopic DermatitisNCT04504279Forte Biosciences, Inc.154
已完成
4 期
Investigation of Efficacy and Safety of EPOGAMNeurodermatitisAtopic DermatitisNCT00878670Max Zeller Soehne AG23
终止
4 期
Tralokinumab for Dupilumab FailuresAtopic DermatitisNCT06773455Psoriasis Treatment Center of Central New Jersey7
招募中
不适用
A Study of Adalimumab in Acute Vogt-Koyanagi-Harada DiseaseVogt-Koyanagi-Harada DiseaseAdalimumabNCT05590416Tianjin Medical University15